Quest Diagnostics (DGX) – Company Press Releases
-
Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
-
Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease
-
Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay
-
Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease
-
Quest Diagnostics to Release First Quarter 2024 Financial Results on April 23, 2024
-
First PFAS "Forever Chemicals" Consumer-Initiated Blood Test With Physician Consult Launches on questhealth.com
-
Ten Years Running: FORTUNE Names Quest Diagnostics One of 2024 "World's Most Admired Companies"
-
Quest Diagnostics to Speak at the Barclays 26th Annual Global Healthcare Conference
-
Quest Diagnostics and Instacart Collaborate To Reduce Food Insecurity Across the United States With Integrated Patient Health Coaching and Nutritious Grocery Delivery
-
Quest Diagnostics and Instacart Collaborate to Reduce Food Insecurity Across the United States with Integrated Patient Health Coaching and Nutritious Grocery Delivery
-
Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection
-
Quest Diagnostics Debuts MelaNodal Predict™ Test, Personalizing Melanoma Risk Prediction to Help Patients Forgo Invasive Surgery
-
First PFAS "Forever Chemicals" Consumer-Initiated Blood Test with Physician Consult Launches on questhealth.com
-
Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share
-
Ten Years Running: FORTUNE Names Quest Diagnostics one of 2024 "World's Most Admired Companies"
-
Fitbit and Quest Diagnostics Collaborate To Advance Research on the Use of Wearable Devices To Improve Metabolic Health
-
Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus' TLR9 agonist in hepatocellular carcinoma, intrahepatic
-
Quest Diagnostics to Release Fourth Quarter and Full Year 2023 Financial Results on February 1, 2024
-
Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health
-
Quest Diagnostics and Ultima Collaborate to Scale Ultima’s Technology in Fast-Growing Minimal Residual Disease and Whole Genome Sequencing
-
Quest Diagnostics Acquires Select Assets of Outreach Lab Services Business of Steward Health Care System
-
Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD™ technology in phase II clinical trial for unresectable stage III NSCLC
-
Quest Diagnostics to Speak at the 42nd Annual J.P. Morgan Healthcare Conference
-
Quest Diagnostics Names Yuri A. Fesko, M.D., Senior Vice President and Chief Medical Officer
-
Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis
-
Quest Diagnostics Launches New 88-Compound Novel Psychoactive Substance Test Panel
-
Quest Diagnostics Receives Perfect Score on Human Rights Campaign Foundation’s Corporate Equality Index for Seventh Consecutive Year
-
Haystack Oncology and Rutgers Cancer Institute Collaborate to use Haystack MRD™ in Clinical Study of Early-Stage Triple-Negative Breast Cancer
-
Universal DX Announces Strategic Collaboration With Quest Diagnostics To Bring Advanced Colorectal Cancer Screening Blood Test to Patients and Providers in the United States
-
Quest Diagnostics and CDC Expand Public Health Research Collaboration to Better Understand Hepatitis C Burden in the United States
-
Quest Diagnostics Receives Perfect Score on Human Rights Campaign Foundation's Corporate Equality Index for Seventh Consecutive Year
-
Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis
-
Universal DX Announces Strategic Collaboration with Quest Diagnostics to Bring Advanced Colorectal Cancer Screening Blood Test to Patients and Providers in the United States
-
Quest Diagnostics Declares Quarterly Cash Dividend
-
Quest Diagnostics Launches Mobile Phlebotomy Service, Enabling Convenient At-Home Specimen Collection in the United States
-
Quest Diagnostics Prices $750 Million of Senior Notes
-
Diadem SpA Announces Exclusive U.S. Licensing Agreement with Quest Diagnostics for Its AlzoSure® Predict Alzheimer's Disease Prognostic Technology
-
Quest Diagnostics Reports Third Quarter 2023 Financial Results; Updates Guidance for Full Year 2023
-
Neway Forms Lab Services Agreement with Quest Diagnostics to Speed Quality ESRD Testing
-
Quest Diagnostics to Release Third Quarter 2023 Financial Results on October 24, 2023
-
Quest Diagnostics to Speak at the Baird 2023 Global Healthcare Conference
-
Quest Diagnostics Releases 2022 Corporate Responsibility Report
-
Quest Diagnostics Releases 2022 Corporate Responsibility Report
-
Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) Test
-
Quest Diagnostics Declares Quarterly Cash Dividend
-
Inflammation Marker Signifies Increased Mortality Risk, Finds New Study in PLOS ONE
-
Quest Introduces First-To-Market Consumer-Initiated Blood Test for Alzheimer's Disease Risk Assessment on questhealth.com
-
Quest Diagnostics Reports Second Quarter 2023 Financial Results; Updates Guidance for Full Year 2023
-
Quest Diagnostics Named a 'Best Place To Work for Disability Inclusion' for Sixth Consecutive Year
-
Quest Diagnostics Launches Novel Prostate Cancer Test Aimed at Improving Diagnosis and Grading
Back to DGX Stock Lookup
